- Home
- LDI vs SLN Comparison
LDI vs SLN Comparison
Compare LDI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- SLN
- Stock Information
- Founded
- LDI 2010
- SLN 1994
- Country
- LDI United States
- SLN United Kingdom
- Employees
- LDI N/A
- SLN N/A
- Industry
- LDI Finance: Consumer Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- LDI Finance
- SLN Health Care
- Exchange
- LDI Nasdaq
- SLN Nasdaq
- Market Cap
- LDI 314.1M
- SLN 352.2M
- IPO Year
- LDI 2021
- SLN N/A
- Fundamental
- Price
- LDI $1.61
- SLN $4.79
- Analyst Decision
- LDI Sell
- SLN Buy
- Analyst Count
- LDI 3
- SLN 4
- Target Price
- LDI $2.60
- SLN $46.25
- AVG Volume (30 Days)
- LDI 645.0K
- SLN 339.1K
- Earning Date
- LDI 03-11-2025
- SLN 02-27-2025
- Dividend Yield
- LDI N/A
- SLN N/A
- EPS Growth
- LDI N/A
- SLN N/A
- EPS
- LDI N/A
- SLN N/A
- Revenue
- LDI $1,013,388,000.00
- SLN $21,773,221.00
- Revenue This Year
- LDI N/A
- SLN N/A
- Revenue Next Year
- LDI $21.63
- SLN $104.98
- P/E Ratio
- LDI N/A
- SLN N/A
- Revenue Growth
- LDI 10.36
- SLN N/A
- 52 Week Low
- LDI $1.52
- SLN $4.06
- 52 Week High
- LDI $3.23
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- LDI 40.22
- SLN 41.33
- Support Level
- LDI $1.54
- SLN $4.71
- Resistance Level
- LDI $1.72
- SLN $5.16
- Average True Range (ATR)
- LDI 0.07
- SLN 0.47
- MACD
- LDI 0.01
- SLN 0.08
- Stochastic Oscillator
- LDI 32.73
- SLN 32.74
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.